Menta Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Menta Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-56,400	Closed	-$884K	–	592
2019 Q1	$884K	Buy	+56,400	New	+$995K	0.39%	74
2016 Q4	–	Sell	-213,408	Closed	-$9.82M	–	966
2016 Q3	$9.82M	Buy	+213,408	New	+$11.1M	0.94%	2
2016 Q2	–	Sell	-140,300	Closed	-$7.51M	–	979
2016 Q1	$7.51M	Buy	140,300 +61,500	+78%	+$3.61M	1.03%	4
2015 Q4	$5.17M	Sell	78,800 -8,400	-10%	-$519K	0.66%	7
2015 Q3	$4.92M	Buy	87,200 +14,000	+19%	+$908K	0.78%	1
2015 Q2	$4.33M	Buy	73,200 +21,400	+41%	+$1.32M	0.71%	1
2015 Q1	$3.23M	Buy	51,800 +21,400	+70%	+$1.24M	0.42%	46
2014 Q4	$1.75M	Buy	30,400 +6,200	+26%	+$345K	0.25%	119
2014 Q3	$1.3M	Buy	+24,200	New	+$1.28M	0.21%	142

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Menta Capital's TEVA Position: Q2 2019 in Review

Menta Capital sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 56,400 shares — an estimated $884K sold.

Menta Capital first reported a position in TEVA in Q3 2014 and held it in 9 quarters. The position peaked at $9.82M in Q3 2016. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

Menta Capital reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Menta Capital sold 56,400 Teva Pharmaceuticals shares in Q2 2019, an estimated $884K.
Menta Capital first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 9 quarters.
Menta Capital's Teva Pharmaceuticals position peaked at $9.82M in Q3 2016.
452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Menta Capital's 13F filing for Q2 2019, filed 7 Aug 2019.